On 12 Nov 2026 Merck & Co. closed at $146.95, +42.5% this year; market cap $364.88bn, P/E 148.8.
Health Care · Pharmaceuticals · NYSE · United States
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
| Market cap | $364.88bn |
| P/E (trailing) | 148.8 |
| EPS (TTM) | $0.99 |
| Beta | 0.12 |
| Dividend | $3.40 |
| Dividend yield | 2.31% |
| Ex-dividend date | 15 Sep 2026 |
| Latest report | 29 Oct 2026 |
| Next earnings | 30 Jan 2027 |
| YTD | +42.5% |
| 1Y | +65.4% |
| 3Y | +16.3% |
| 5Y | +15.3% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $64.93bn | $18.25bn | $12.36bn |
| 2024 | $64.17bn | $17.12bn | $18.10bn |
| 2023 | $60.12bn | $365.00m | $9.14bn |
| 2022 | $59.28bn | $14.52bn | $14.71bn |
| 2021 | $48.70bn | $13.05bn | $9.66bn |
Base value $164.04 (+11.6% vs price); 1 of 1 methods above the price. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.